| Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms O Wolach, RS Sellar, K Martinod, D Cherpokova, M McConkey, ... Science translational medicine 10 (436), eaan8292, 2018 | 438 | 2018 |
| Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation S Elf, NS Abdelfattah, E Chen, J Perales-Patón, EA Rosen, A Ko, ... Cancer discovery 6 (4), 368-381, 2016 | 293 | 2016 |
| Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature O Wolach, O Bairey, M Lahav Medicine 89 (5), 308-318, 2010 | 189 | 2010 |
| How I treat mixed-phenotype acute leukemia O Wolach, RM Stone Blood, The Journal of the American Society of Hematology 125 (16), 2477-2485, 2015 | 186 | 2015 |
| Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric‐inspired regimens: systematic review and meta‐analysis R Ram, O Wolach, L Vidal, A Gafter‐Gvili, O Shpilberg, P Raanani American journal of hematology 87 (5), 472-478, 2012 | 181 | 2012 |
| Lymphoma and leukemia cells possess fractal dimensions that correlate with their biological features A Mashiah, O Wolach, J Sandbank, O Uziel, P Raanani, M Lahav Acta haematologica 119 (3), 142-150, 2008 | 83 | 2008 |
| Long‐term follow‐up of VIALE‐A: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia KW Pratz, BA Jonas, V Pullarkat, MJ Thirman, JS Garcia, H Döhner, ... American journal of hematology 99 (4), 615-624, 2024 | 75 | 2024 |
| Infections associated with chronic granulomatous disease: linking genetics to phenotypic expression J Ben-Ari, O Wolach, R Gavrieli, B Wolach Expert review of anti-infective therapy 10 (8), 881-894, 2012 | 74 | 2012 |
| Neutropenia after rituximab treatment: new insights on a late complication O Wolach, O Shpilberg, M Lahav Current opinion in hematology 19 (1), 32-38, 2012 | 72 | 2012 |
| Mixed-phenotype acute leukemia: current challenges in diagnosis and therapy O Wolach, RM Stone Current Opinion in Hematology 24 (2), 139-145, 2017 | 71 | 2017 |
| Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents—a multicenter historical prospective study R Ram, O Amit, T Zuckerman, R Gurion, P Raanani, Y Bar-On, I Avivi, ... Annals of hematology 98, 1927-1932, 2019 | 68 | 2019 |
| Autoimmunity and inflammation in myelodysplastic syndromes O Wolach, R Stone Acta haematologica 136 (2), 108-117, 2016 | 67 | 2016 |
| Leucocyte adhesion deficiency—A multicentre national experience B Wolach, R Gavrieli, O Wolach, T Stauber, O Abuzaitoun, A Kuperman, ... European Journal of Clinical Investigation 49 (2), e13047, 2019 | 58 | 2019 |
| Characterisation of blood-derived exosomal hTERT mRNA secretion in cancer patients: a potential pan-cancer marker H Goldvaser, A Gutkin, E Beery, Y Edel, J Nordenberg, O Wolach, ... British journal of cancer 117 (3), 353-357, 2017 | 58 | 2017 |
| Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation. Cancer Discov. 2016; 6: 368–381. doi: 10.1158/2159-8290 S Elf, NS Abdelfattah, E Chen, J Perales-Patón, EA Rosen, A Ko, ... Go to original source... Go to PubMed, 2018 | 54 | 2018 |
| Targeted next generation sequencing for the diagnosis of patients with rare congenital anemias N Shefer Averbuch, O Steinberg‐Shemer, O Dgany, T Krasnov, ... European Journal of Haematology 101 (3), 297-304, 2018 | 43 | 2018 |
| Long-term follow-up of the phase 3 viale-a clinical trial of venetoclax plus azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy KW Pratz, BA Jonas, VA Pullarkat, MJ Thirman, JS Garcia, W Fiedler, ... Blood 140 (Supplement 1), 529-531, 2022 | 42 | 2022 |
| Venetoclax is safe and efficacious in relapsed/refractory AML C Ganzel, R Ram, A Gural, O Wolach, S Gino-Moor, V Vainstein, ... Leukemia & Lymphoma 61 (9), 2221-2225, 2020 | 36 | 2020 |
| Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B‐cell precursor acute lymphoblastic leukemia: report from the Israeli Study Group of … S Elitzur, N Arad‐Cohen, S Barzilai‐Birenboim, M Ben‐Harush, B Bielorai, ... Pediatric Blood & Cancer 66 (10), e27898, 2019 | 31 | 2019 |
| Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato‐oncological patients: randomized controlled trial M Paul, R Ram, E Kugler, L Farbman, A Peck, L Leibovici, M Lahav, ... American journal of hematology 89 (3), 243-248, 2014 | 30 | 2014 |
